The GPR171 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1299 human lung carcinoma cell line. This product provides a genetically disrupted GPR171 locus across the cell pool, enabling loss-of-function studies of the orphan G protein-coupled receptor GPR171 in a metastatic lung adenocarcinoma background. The heterogeneous knockout population is suitable for experiments where clonal variability may be averaged or when studying bulk population responses to genetic ablation of the target gene.
The host cell line NCI-H1299 is an epithelial cell line originally isolated from a lymph node metastasis of a lung adenocarcinoma. It is widely employed as a model for non-small cell lung cancer, particularly metastatic and invasive phenotypes. NCI-H1299 cells exhibit characteristic properties of advanced lung carcinoma, including anchorage-independent growth and high migratory capacity, making them valuable for investigating tumor progression, metastasis, and therapeutic resistance mechanisms.
GPR171 is an orphan GPCR that is activated by the endogenous peptide ligands BigLEN and proSAAS. Upon activation, it couples primarily to G??i/o proteins, leading to inhibition of adenylyl cyclase and a consequent reduction in intracellular cAMP levels. This downregulation of cAMP attenuates protein kinase A (PKA) activity and subsequent phosphorylation of the cAMP response element-binding protein (CREB). Additionally, GPR171 signaling engages the MAPK/ERK pathway and interacts with ??-arrestin, linking receptor activation to diverse downstream effectors. In hematopoietic systems, GPR171 plays a role in stem cell maintenance and immune regulation, but its functions in lung epithelial cells are less characterized, creating opportunities for discovery.
In the context of lung carcinoma, GPR171 may modulate cAMP-dependent signaling pathways that influence cell proliferation, survival, and motility. By disrupting GPR171 expression in NCI-H1299 cells, researchers can interrogate how this receptor contributes to lung cancer cell behavior under baseline and stimulated conditions. The polyclonal knockout population permits assessment of GPR171-mediated effects on GPCR-G??i-adenylyl cyclase-cAMP-PKA-CREB axis activity and its crosstalk with MAPK/ERK signaling, potentially revealing molecular vulnerabilities in metastatic lung adenocarcinoma.
Typical research applications include functional characterization of GPR171 in lung cancer using western blotting, RT-qPCR, and cAMP ELISA to confirm gene disruption and assess signaling changes. Cell proliferation, migration/invasion, and drug sensitivity assays enable evaluation of phenotypic consequences of GPR171 loss. Moreover, these cells serve as a platform for screening GPR171 modulators or studying the interplay between GPR171 and other oncogenic pathways. The polyclonal format supports robust statistical analysis in pooled knockout experiments. For further technical details and ordering information, contact Ascent Research.
